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Abstract
The diagnosis of infectious diseases has been 
revolutionized by the development of molecular techniques, 
foremost with the applications of the polymerase chain 
reaction (PCR). The achievable high sensitivity and ease 
with which the method can be used to detect any known 
genetic sequence have led to its wide application in the 
life sciences. More recently, real-time PCR assays have 
provided additional major contributions, with the inclusion 
of an additional fluorescent probe detection system 
resulting in an increase in sensitivity over conventional 
PCR, the ability to confirm the amplification product and 
to quantitate the target concentration. Further, nucleotide 
sequence analysis of the amplification products has 
facilitated epidemiological studies of infectious disease 
outbreaks, and the monitoring of treatment outcomes 
for infections, in particular with viruses which mutate at 
high frequency. This review discusses the applications of 
qualitative and quantitative real-time PCR, nested PCR, 
multiplex PCR, nucleotide sequence analysis of amplified 
products and quality assurance with nucleic acid testing 
(NAT) in diagnostic laboratories.
Introduction
As with most bioscience disciplines, the diagnosis of 
human virological disease has been revolutionized by the 
development of molecular techniques. While this influence 
is now well over a decade old, the impact remains ongoing 
and the transition far from complete. Although various 
molecular techniques have been available for decades, 
it has only been in recent years that the technologies 
have matured sufficiently to make their diagnostic 
use viable. Foremost has been the development 
of real-time PCR, combining product detection and 
confirmation using very sensitive hybridisation probes, 
with target quantitation if desired, in a very rapid assay. 
Gene sequencing has additionally made a significant 
contribution. The combination of economical and rapid 
sequencing chemistries, computer-based phylogenetic 
analysis software and electronic interrogation of Internet-
accessible gene sequence databases, has facilitated 
the use of molecular systematics to directly assist 
patient management, both for individual patients as in 
drug resistance testing, and within the community for 
the epidemiological analysis of infectious outbreaks. 
The scope of this review does not allow an exhaustive 
analysis of the molecular techniques available or in 
use for the detection of all medically important viruses. 
However, it is vital to first concentrate on the universal 
issue of assuring result accuracy, without which any 
test is meaningless. This will be followed by specific 
representative examples illustrating the use of molecular 
techniques for the diagnosis and management of human 
virological diseases.
Result quality assurance
Result quality is paramount and achievable only when 
all aspects of the test procedure are satisfactorily 
understood. This begins with the design, development 
and validation of the test for the range of specimen types, 
collection conditions and sample quality for which the 
test is expected to function (Table 1). These performance 
criteria are predominantly provided for commercial test 
kits but for in-house tests each aspect must be assessed 
in detail and the validation analyses documented before 
the use of such tests is valid. Once a test is implemented, 
irrespective of the source of the test, the ongoing 
performance must be carefully monitored, and problems 
documented, to ensure result quality is maintained. 
Laboratory design and staff competency also play crucial 
roles (Table 1). Typically quality assurance issues are 
detailed in national standards and guidelines for which 
compliance is obligatory to achieve good laboratory 
practice, and frequently mandated to achieve legislated 
accreditation.
The causes of false results
Each assay batch must contain adequate positive and 
negative controls to confirm test performance. They need 
to be chosen to ensure the validity of each and every 
step; nucleic acid extraction, preparation of reagent 
master-mixes, aliquoting of nucleic acid, amplification 
and detection. The inclusion of weakly positive control 
material, where the concentration of nucleic acid is just 
above the limit of detection, should be used to assess 
the performance of the whole test procedure, including 
extraction, to ensure test sensitivity is maintained for 
each batch. A negative patient sample is also essential, 
and should always be processed last at each step, after 
any positive controls, to ensure sample contamination 
is not occurring. Additional negative controls should be 
spaced throughout large assay batches. A master-mix 
negative water control, not opened during the aliquoting 
of nucleic acid, is also advised to confirm the master-
mix is uncontaminated. Even when the performance 
of controls is adequate, clusters of positive results, 
especially following a strongly positive sample, should be 
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Table 1. Summary of quality assurance issues to be addressed
Sample
 suitability and variability
 collection, transport and storage
 contamination during prior sampling
 sample aliquoting
 extraction of nucleic acid, presence of inhibitors
Virus stability
Equipment performance
Laboratory design, air and work flow
Method validation
 suitability and diagnostic relevance
 robustness
 sensitivity
 broad reactivity
 negative and weak positive controls
 detecting inhibition
Reagent storage
Staff competency
Record keeping
viewed with suspicion until the suspect samples can be 
re-extracted and retested to confirm the result.
Contamination
The elimination of false results requires an understanding 
of their causes (Table 2). With PCR-based tests, where 
the same methods are performed repeatedly, the potential 
for contamination of new tests with amplified product 
(amplicon) from previous amplifications of the same 
target sequence poses by far the greatest risk, and is the 
commonest cause of false positive results. It is essential 
that the functions of (a) PCR reagent storage and master 
mix preparation, (b) nucleic acid extraction, (c) addition of 
nucleic acid to PCR mixes, and (d) PCR amplification and 
post-PCR manipulation, e.g. running of gels, sequencing 
or cloning of products, are physically separated, with 
independent airflows, to minimize contamination. Ideally, 
each should be performed in physically separated rooms. 
A unidirectional workflow from one function to the next 
is essential to eliminate the risk of contamination to set 
up areas with previously amplified product. Each area 
must have its own dedicated pipettors, equipment, 
consumables and staff personal protective equipment, 
e.g. lab gowns/coats and gloves. Staff must be well 
trained and employ scrupulous sterile technique. If racks 
need to be returned against the unidirectional workflow, 
they must first be disinfected in 2% sodium hypochlorite 
or the equivalent for 4 hours. PCR-certified filtered tips 
should be used at all stages, and reagent, sample and 
PCR tubes should be kept capped, only opening when 
specifically required. The use of ganged cap strips should 
be avoided, as the latter requirement cannot be achieved. 
Ganged strips of tubes with individually attached caps are 
available and should be preferred. Post-use wiping down 
of work areas and pipettes with 2% sodium hypochlorite 
disinfectants and irradiation of the work areas with UV 
light is also good practice. The use of a biohazard hood 
is advised for steps 1 to 3 above, both as a protection 
from potentially infectious agents for the operator and 
to reduce the risk of sample contamination. While the 
HEPA filters in such cabinets are typically rated to 0.3 µm, 
smaller particles such as many viruses and nucleic acid 
molecules are also likely to be efficiently retained. Viruses 
are often aggregated, attached or contained within larger 
particles such as cells, and molecular interactions such as 
electrostatic attraction and Brownian motion, rather than 
size exclusion, are likely to efficiently retain nucleic acid 
molecules. However, such cabinets used for manipulating 
post-amplification products, e.g. during two-tube nested 
amplification, should be externally vented, to ensure that 
any amplicons which pass through the filters into the 
exhaust are not recirculated. The use of dUTP to replace 
dTTP in the PCR master mix, and the incorporation of 
Uracil-DNA Glycosylase (UNG) to degrade previously 
amplified uracil-containing contaminating amplicons, a 
method commonly incorporated in commercial kits, should 
also be considered to eliminate contamination although 
it is only effective when the level of contamination is 
low. However, residual UNG activity may remain after 
amplification, so PCR samples should be stored at -
20°C if immediate analysis of the product is not possible. 
In addition, the use of dUTP and UNG is problematic 
for one-step RT-PCR, necessitating the use of a heat-
stable reverse transcriptase, active above 60°C, to 
prevent the cDNA being degraded before PCR. Such 
RT-PCR requirements and conditions may reduce assay 
sensitivity.
Samples submitted to a diagnostic laboratory 
are frequently used for multiple tests. Biochemical or 
haematological tests processed by auto-analysers are 
typically performed first before the specimen is forwarded 
for virological testing. Such auto-analysers can cross-
contaminate specimens during injection sampling. Setting 
aside an aliquot specifically for molecular testing resolves 
this problem, but introduces the risk of transcription and 
aliquoting errors, and specimens can be too limited for 
adequate splitting.
Inhibition
The presence of inhibitors to the amplification reaction, 
such as haemoglobin, lactoferrin and bile salts, within the 
sample is the major cause of false negative results (Al-
Soud et al., 2005; Al-Soud and Radstrom, 2001). Most 
commercial nucleic acid extraction systems incorporating 
a spin or vacuum column allow for efficient removal of 
inhibitors because the nucleic acid trapped in the silica-
gel membrane can be very effectively washed before 
elution. Similarly, methods incorporating magnetic 
bead techniques to capture and retain nucleic acid also 
Table 2. Summary of the causes of false results
False positive results
Contamination from:
• Prior sample testing by autoanalysers
• Amplicons from previous amplifications of the same target
Aliquoting errors; sample or reagents
Transcription errors during resulting and record keeping
The cause of false negative results
Presence of inhibitors in the sample
Degraded samples
Strain diversity reducion
• Primer target homology
• Probe target homology (real-time PCR)
Degraded reagents
Malfunctioning equipment
Aliquoting errors; sample or reagents
Transcription errors during resulting and record keeping
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achieve high recovery and purity rates. However, some 
samples will remain inhibitory and such samples need to 
be identified with the use of effective inhibition controls. 
One method is to assay for the presence of nucleic acid 
either intrinsically present in the sample or added (either 
virus particles or nucleic acid) as a control, which will 
be co-extracted so as to act both as an extraction and 
an inhibition control. Such control nucleic acid should 
be present only at levels close to the limit of the assay, 
to provide a realistic assessment of the presence of 
inhibitors. Due to the potential reduction in amplification 
sensitivity when combining both a separate inhibition 
control target and the test target in a multiplex reaction, 
we prefer to perform a duplicate inhibition control for each 
sample spiked with the low positive control. However, 
such multiplex, simultaneous testing of test and inhibition 
control targets may be acceptable if maximum sensitivity 
is not required. Inhibition controls in some specimen types 
can be forgone if the rate of inhibition has been confirmed 
as very low e.g. CSF. Samples containing inhibitors can 
be further treated with chelating agents such as Chelex 
100 (Bio-Rad Laboratories, Hercules, CA, USA) chelating 
resin, for removal of divalent metal cations or diluted 
until the inhibition is no longer detectable, mindful that 
these steps will reduce the test sensitivity. During the 
development phase, if inhibition is a problem because of 
the nature of the samples being tested e.g. faeces, the 
inclusion of amplification facilitators such as bovine serum 
albumin and betaine to minimize inhibition problems 
should be considered (Abu Al-Soud and Radstrom, 2000). 
In addition, some polymerases may better tolerate the 
presence of inhibitors than others (Al-Soud et al., 2005).
Target homology
Primer and probe target sites are ideally chosen from 
the regions of the genome conserved among the strains 
of the virus to be detected. Often this is to functionally 
constrained regions within protein-encoding non-structural 
genes, to ensure broad reactivity of the test for all wild 
strains of the virus. However, this is not always possible. 
RNA viruses exhibit considerable diversity among wild 
strains. For instance, although known strain diversity at 
the target site is accommodated within the primer and 
probe design, the genetic diversity of some viruses, such 
as caliciviruses and HIV, exceeds the ability of the test 
to detect all strains without loss of sensitivity. Reducing 
the annealing temperature may allow satisfactory priming 
even in the presence of several target/primer nucleotide 
mismatches, unless close to or at the 3′ end of the primer. 
However, this does increase the likelihood of non-specific 
amplification, so validity of any product must be confirmed. 
The incorporation of ‘universal’ nucleotide bases, such 
as inosine, can effectively accommodate extreme strain 
diversity at particular primer or probe sites but the results 
are variable and sensitivity can be compromized. Our 
experience suggests limiting the use of inosine to as 
few sites as possible and certainly no more than three 
separated primer sites not close to the 3′ end of the 
primer. In addition, some polymerases appear to exhibit 
better tolerance to the presence of inosine than others and 
amplification efficiency may be enhanced if the extension 
temperature is reduced to as low as 60°C. Sequencing 
such product can be problematic, as inosine-containing 
primers may inadequately prime dye terminator cycle 
sequencing reactions.
Where fluorescent probes are being used to detect 
the presence of amplification products, it is possible 
that amplification has occurred but sequence variation 
in the amplicon prevents probe hybridisation. During 
the test development phase, when the method is being 
compared with other tests, but also for critical specimens, 
anomalous negative results should be checked using gel 
electrophoresis and UV-illuminated ethidium bromide 
staining. The sequence of the probe target of any 
amplicons present can then be characterized to ascertain 
and correct the cause of the lack of hybridisation in a 
redesigned probe.
Just as specificity is the great advantage of PCR, it 
is also its Achilles heal, in that unknown strain diversity 
will remain undetected. For viruses where sequence 
diversity among strains is high, the design of primers 
and probes needs to be constantly reviewed in the light 
of newly published sequences. Even as few as one or 
two mismatches in a primer can reduce amplification 
efficiency, and within a fluorescent probe, reduce or 
eliminate the strength of the fluorescence signal. The 
latter is especially true for DNA probes conjugated to 
other DNA binders such as minor groove binding (MGB) 
groups to assist in probe binding. This shortens the DNA 
sequence required for 3′-MGB probes to achieve the 
same melting temperature (Tm) increasing the specificity 
of the probe (Kutyavin et al., 2000). While this is highly 
advantageous to increase assay specificity, such probes 
are also more vulnerable to mismatches from viral strain 
sequence diversity. Consequently, a false negative result 
due to strain diversity is always possible and important 
clinically relevant specimens should be examined by 
alternative methods.
Poorly maintained equipment and reagents
The optimal performance of molecular tests is often 
restricted to narrow limits in temperature and reagent 
volumes, and poorly maintained equipment can introduce 
sufficient errors for the test to fail. The performance 
and accuracy of all equipment such as pipettors and 
theromocyclers must be routinely checked to ensure they 
are performing within specifications. While controls are 
included within each test batch as an early warning that 
an error has occurred, it is possible for malfunctioning 
equipment to remain undetected if this is the only 
check of valid performance. For instance, peltier-type 
thermocyclers can have more than one peltier cell per 
heating block and should one of these peltier cells fail, 
that zone of the block will not achieve the correct cycle 
temperatures. Furthermore, the performance failure 
may go undetected if the control samples happen to be 
constantly located in the normal functioning regions of the 
block. For this reason all equipment must be maintained 
and performance regularly checked and documented 
in line with the manufacturer’s recommendations and 
specifications.
Similarly, poor reagent storage protocols, especially 
where such reagents are subject to repeated freeze-thaw, 
will quickly reduce enzyme potency, decreasing assay 
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sensitivity and causing false negatives. RNA is especially 
fragile and rapidly degraded by ubiquitously present 
RNAses. If a weakly positive control is not included in 
each assay batch, the reduced sensitivity may remain 
undetected. The assay protocols should detail how 
reagents are to be aliquoted, stored and used to prevent 
degradation of reagent potency.
Collection, transport, storage and extraction of 
samples
Even a well performing assay will not resurrect the 
loss of sample integrity due to inadequate collection or 
handling of the sample. Protocols should be devised to 
describe adequate performance of each step of sample 
handling, from acceptable patient samples and collection 
techniques, transport to the laboratory, and storage of 
the sample and extracted nucleic acid prior to testing. 
The latter is especially important for RNA, which is 
easily sheared during freeze–thaw cycles and subject 
to degradation by nucleases. Sub-optimal performance 
of any of these specimen collection or handling steps 
may result in falsely negative tests. The performance of 
the assay should be validated for such protocols, and 
specimens rejected when they don’t comply.
Assay sensitivity
One of the significant advantages of molecular assays is 
the high degree of sensitivity; detection of less than 10 
copies even for RNA targets can be achieved, if the assay 
is well designed and the sample integrity is maintained 
throughout collection, transport, extraction and storage. 
In addition, while these latter issues have been rightly 
emphasized, molecular tests can detect the presence of 
nucleic acid when the virus is no longer viable, perhaps 
the result of patient therapy or after prolonged sample 
storage. The latter is especially useful for retrospective 
analysis of undiagnosed disease after new infectious 
agents are discovered. However, the increased sensitivity 
which can be achieved with such tests and the ability to 
detect non-viable infectious agents may require a careful 
assessment of result interpretation, e.g. for viruses which 
may be carried in low numbers asymptomatically, or post-
therapy.
Molecular assays requiring genetic amplification 
based on the polymerase chain reaction (PCR) now 
dominate the molecular detection of human viruses. Such 
assays are rapid, sensitive and easily adapted to target 
any known genetic sequence. The inclusion of a prior 
reverse transcription (RT) step facilitates the detection 
of RNA viruses. Sufficient sensitivity can be achieved 
in a single reaction of 25–40 cycles for many diagnostic 
tests where the ability to detect very low numbers of virus 
particles is not required. Sensitivity can be increased by 
either (a) a nested reaction, or (b) real-time fluorescent 
assay. In the former, the additional cycles can increase 
sensitivity by at least 100-fold. A similar improvement in 
sensitivity is achieved in the latter, due to the increases 
sensitivity attained by the fluorescent detection system. 
The latter requires more expensive reagents and 
equipment, but also can offer product confirmation and 
quantitation. Three examples of PCR are outlined; nested 
RT-PCR, real-time PCR and quantitative PCR.
Nested RT-PCR for the detection and typing of 
norovirus
Caliciviruses are a major cause of acute gastroenteritis, 
and the species Norovirus (previously Norwalk-like virus) 
is the most common cause of such disease associated 
with outbreaks (Glass et al., 2000). Being RNA viruses, 
the genome diversity among norovirus strains challenges 
the broad reactivity of any test to detect them. As antigen-
based ELISA tests were unreliable, it was not until the 
early 90s and the development of RT-PCR tests, that the 
significance of noroviruses could be understood. The 
genome of approximately 7500 bp encodes three open 
reading frames (ORF). The first, ORF-1 contains the non-
structural genes which encode a helicase, a protease and 
a polymerase. The functionally constrained regions of the 
latter, designated Regions A and B, are the most common 
targets chosen for RT-PCR assays to detect their presence 
in stool samples (Ando et al., 2000; Fankhauser et al., 
2002; Jiang et al., 1999). More recently, real-time assays 
targeting the 3′-end of the ORF-1 have been developed 
(Kageyama et al., 2003, Trujillo et al., 2006). To detect 
the very low numbers of virions potentially present in the 
faeces of patients in early or late infection we designed 
a closed-system nested RT-PCR method. While single-
tube nested methods have been published (Olmos et al., 
1999; Wolff et al., 1995), they often incorporate awkward 
and unwieldy mechanisms to contain the nested reagents 
during primary amplification. We ascertained that the 
nested reagents could be stably contained in the tube cap 
as a simple hanging drop supported by the innate surface 
tension of the reagents, requiring only a short microfuge 
centrifugation at the end of the primary amplification to 
combine the reagents for the nested reaction (Ratcliff et 
al., 2002). Because a heated lid cannot be used during 
the primary amplification, the primary reagents must 
be overlaid with paraffin oil to prevent evaporation. 
Comparative tests established that this nested ‘hanging-
drop’ single-tube RT-PCR method increased sensitivity 
by at least 100-fold (see Fig. 1), similar to two-tube 
nested methods, but without the significant contamination 
risks normally associated with such nested reactions. In 
addition, having the extra set of primers can benefit the 
rate of detection of genetically variable viruses. Where in a 
single amplification, a variable target at one primer site will 
typically prevent amplification, in this nested method it is 
possible that product may still be amplified by combinations 
of the other primers present. However, the primary 
antisense (reverse) primer must be homologous, as it 
primes the RT step for one-tube reactions. Our experience 
with this method highlights the need to continually assess 
test performance. After months of reliable performance, a 
loss of sensitivity was detected based on the performance 
of the controls. Analysis of the assay revealed that the 
AMV reverse transcriptase in the primary reaction was 
now inhibitory to the polymerase used in the nested 
reaction. Neither manufacturer reported any modification 
of these enzymes. Satisfactory resolution of the problem 
was achieved by diluting the AMV reverse transcriptase to 
0.05 Units per reaction and using Amplitaq Gold (Applied 
Biosystems, Inc. [ABI], Foster City, Calif.) and GeneAmp 
10× Buffer II (ABI) in both primary and nested reactions 
as per the manufacturer’s specifications. Although the 
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Fig.  1. Typical amplification patterns for ten-fold serially diluted faecal RNA extracts containing Norovirus genotype 2 using (a) RT-PCR (lanes 2–5) and (b) 
one-tube “hanging drop” nested RT-PCR (lanes 6–12), showing a 100-fold increase in sensitivity with the latter method. Reproduced with kind permission 
(American Society for Microbiology Journals Department) from Ratcliff et al., 2002. RT-PCR (a) single amplification with the primary amplification reagents 
produces a 326bp product. Single-tube nested RT-PCR (b) sequentially amplifying for primary and secondary nested products, produces the primary 
amplification product at high target copy number, and the additional 210bp nested product at low target copy number. Lanes are marked with the RNA 
extract dilution; –1 = 10–1 etc. Also note in the latter method the presence of an intermediate-length product produced by amplification from inner and outer 
primer pairs.
concentration of AMV is very low, the polymerase activity 
is uninhibited and test sensitivity is equivalent to that 
previously published.
Real-time PCR
The advantages of a rapid assay time, and an inbuilt 
detection system which can offer product confirmation and 
quantitation, with an electronic result output which lends 
itself to high through-put electronic reporting typically 
required in a diagnostic laboratory, has guaranteed that 
real-time PCR will make a major contribution to the 
diagnosis of infectious disease. Most conventional PCR-
based testing formats involve multiple steps of varying 
complexity and open reaction systems, which increase 
the risk for sample contamination by extraneous amplified 
DNA (amplicons). Real-time PCR combines PCR 
amplification with detection of the amplification product 
in the same closed system, resulting in a significantly 
reduced risk of carry-over contamination. In addition, real-
time PCR instruments typically cycle the temperatures 
more rapidly than conventional thermocyclers, and offer a 
much broader dynamic range of up to 107-fold, compared 
to 103-fold in conventional PCR, because of the increased 
sensitivity of the fluorescent detection system.
Real-time PCR technology
Real-time PCR technology is based on the detection and 
quantitation of a fluorescent reporter (Lee et al., 1993; 
Livak et al., 1995), which increases in direct proportion 
to the amount of PCR product in the reaction. The higher 
the starting copy number of the nucleic acid target, the 
sooner a significant increase in fluorescence is observed. 
Fluorescent chemistries commonly used include non-
specific compounds such as the DNA intercalating dyes 
SYBR® green (Schneeberger et al., 1995) and Syto9 
(Monis et al., 2005) or sequence-specific oligoprobes 
that carry a donor and acceptor fluorophor and employ 
Fluorescent Resonance Energy Transfer (FRET) (Hiyoshi 
and Hosoi, 1994). While some product confirmation 
can be achieved with non-specific fluorescent dyes by 
performing denaturation (melting) curve analysis at the 
completion of the amplification, in practice, our experience 
has been that the specific approach yields better results 
for the detection of infectious agents in clinical specimens, 
and particularly so in the determination of pathogen load. 
Commonly, two fluorescence-monitoring systems for DNA 
amplification using specific oligoprobes are used. These 
are (a) dual-labelled probes; and (b) single-labelled 
hybridising probes.
Dual-labelled probes include TaqMan probes (Heid et 
al., 1996), molecular beacons (Mhlanga and Malmberg, 
2001) and scorpion probes (Saha et al., 2001; see also 
Svanvik et al., 2000 for light-up probes). TaqMan probes 
were among the first to be applied in real-time PCR, and 
consist of oligonucleotides that contain a fluorescent dye 
at the 5’ base, and a quenching dye (usually TAMRA) on 
the 3’ base. On excitation by an incident wavelength, the 
fluorescent dye transfers energy to the nearby quenching 
dye molecule rather than releasing fluorescence. TaqMan 
probes are designed to anneal to a complementary 
sequence on a PCR product, and the close proximity 
of the reporter and quencher prevents emission of any 
fluorescence while the probe is intact. As the polymerase 
replicates the template on which a TaqMan probe is bound, 
its 5’ exonuclease activity hydrolyses the probe (Holland 
et al., 1991). This separates the fluorescent and quencher 
dyes resulting in the emission of fluorescence, which 
increases in each cycle proportional to the rate of probe 
cleavage. Accumulation of PCR products is detected by 
monitoring the increase in fluorescence of the reporter 
dye. As mentioned previously, 3’-MGB (Kutyavin et al., 
2000) and other conjugated binding assisting groups, 
92 Ratcliff et al.
have enabled increased specificity with a shorter probe 
such that single-base allelic variation within the probe 
target binding site is possible with well designed probes.
Single-labelled hybridisation probes (or HybProbes) 
are most commonly used with the LightCycler instrument 
(Roche Diagnostics, Basel, Switzerland) (Wittwer et al., 
1997). This technology uses two fluorescently labelled 
oligonucleotides; a donor probe labelled with fluorescent 
dye at the 3’ end and an acceptor probe labelled at the 
5’ end, which absorbs resonance energy from the donor 
probe via FRET. Fluorescence by the acceptor probe will 
only occur when both the donor probe and the acceptor 
probe have annealed to the amplification product in 
close proximity to each other, providing a measure of 
amplification product formation.
The process is non-destructive and reversible, with 
the melting temperature of the hybridisation complex 
being sequence dependent. Melting curve analysis of 
amplification products provides an extra element of 
specificity to the PCR, because sequence variation 
in probe target sites will result in a shift in the melting 
temperature. This may act as an important quality control 
feature that confirms PCR amplicons as the correct 
amplification product, and provides a simple and elegant 
method to genotype mutations, including single base 
mutations (Bernard et al., 1998; Lay and Wittwer, 1997). 
Melting curve analysis can be performed with FRET 
probes and molecular beacons, but not with hydrolysis 
(TaqMan) probes.
Practical applications of real-time PCR in the 
diagnostic laboratory
Review of the current literature shows that many diagnostic 
assays in the infectious diseases laboratory have been 
adapted to a real-time PCR format and this technology is 
now widely used for the detection of bacterial, viral and 
fungal pathogens. It has been particularly important in the 
rapid diagnosis of life-threatening viral diseases such as 
those caused by avian influenza (H5N1) (Whiley et al., 
2005) or herpes simplex (herpes simplex encephalitis) 
(Whiley et al., 2004b). However, significant improvements 
have also been achieved in our laboratory in applying 
real-time PCR protocols for the detection of respiratory 
viruses, the human herpesviruses, enteroviruses, JC virus, 
BK virus, Bordetella pertussis, Mycoplasma pneumoniae, 
Chlamydia trachomatis, Neisseria gonorrhoea as well as 
Aspergillus fumigatus and Pneumocystis jiroveci (Whiley 
et al., 2004a; Whiley et al., 2001; Whiley et al., 2002). 
A comparison of these assays with conventional culture-
based methods convincingly demonstrated greater 
sensitivity of the molecular assays.
Quantitative real-time PCR
The ability of real-time PCR to accurately quantify the viral 
load in clinical specimens has made a major contribution 
as it offers a direct measurement of active viraemia 
(Daar et al., 1991). It offers the possibility to determine 
the dynamics of viral proliferation; a higher viral load may 
correlate with disease progression and virus transmission 
(Kowala-Piaskowska et al., 2004; Mellors et al., 1996). 
The determination of viral load in plasma is particularly 
useful for monitoring the efficacy of antiviral therapy and 
distinguishes between latent and active infections. The 
results can be expressed in absolute terms with reference 
to quantified standards, or in relative terms compared to 
another target sequence present in the sample.
Many quantitative real-time PCR (qPCR) protocols 
for the detection of microbial targets have now been 
published and commercial assays are available for a 
number of clinically important viruses including human 
immunodeficiency virus (HIV) (Kumar et al., 2002; 
O’Doherty et al., 2002), hepatitis B (HBV) and C (HCV) 
viruses (Berger et al., 1998; Kamal et al., 2005; Kowala-
Piaskowska et al., 2004) and cytomegalovirus (CMV) 
(Boeckh and Boivin, 1998). However, the number of 
commercial assays available is still quite limited and this 
has led to the development and introduction of in-house 
real-time qPCR protocols.
Viral load and the pitfalls of quantitative PCR
In order to obtain meaningful results, it is important that the 
efficiency of the qPCR does not vary greatly due to minor 
differences between samples, and careful optimisation 
of the qPCR conditions must be performed. To ensure 
accuracy, a quantitation standard (QS) with known viral 
quantity (e.g. copy number) is incorporated into each 
sample, and carried through sample extraction, reverse 
transcription (RT-PCR), amplification, hybridisation and 
detection. The QS compensates for effects of inhibition 
and controls for the amplification process to ensure the 
accurate quantitation of viral DNA/RNA in each sample. 
Even so, other factors, inherent to the target organism, 
such as genome polymorphism (particularly in RNA 
viruses) can affect the results of both end-point PCR and 
qPCR.
Current Commercial kits for viral load measurement
• PCR/RT-PCR for quantifying DNA or RNA (e.g. 
Roche Cobas Amplicor Monitor [end-point] kits, 
dynamic range: HCV, 600 – 5 x 105 IU/ml and HIV, 
50 – 1 x 106 copies/ml; Roche Cobas Taqman (real-
time) kits, dynamic range: HCV, 43 – 6.9 x 107 IU/ml 
and HIV, 40 – 1 x 107 copies/ml).
• Branched chain DNA signal amplification technology 
for quantifying viral DNA or RNA (e.g. Bayer Versant 
bDNA assays, dynamic range: HCV, 615 to 7,690,000 
IU/ml and HIV, 50–500,000 HIV-1 RNA copies/ml). 
Viral DNA or RNA is hybridized to the microwell surface 
via capture probes. A set of target probes hybridize 
both the viral RNA and the pre-amplifier probes. The 
amplifier probe hybridizes to the pre-amplifier probe 
forming a branched DNA (bDNA) complex. The 
bound bDNA is incubated with an enzyme and then 
with a chemiluminescence substrate.
• Transcription mediated amplification (TMA) for 
quantifying DNA or RNA (e.g. Quest Heptimax HCV 
assay, dynamic range: 5–8.3 x 107 IU/ml). A target 
nucleic acid amplification method that uses RNA 
transcription (RNA polymerase) and DNA synthesis 
(reverse transcriptase) to produce RNA amplicon 
from a target nucleic acid. TMA produces 100–1000 
copies per cycle (RNA) rather than the two copies 
per cycle produced by PCR (DNA).
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• Nucleic acid sequence-based amplification (NASBA) 
for quantifying viral RNA (e.g. Biomerieux NucliSens 
EasyQ HIV-1 assay, dynamic range: 50–3 x 106 IU/
ml). NASBA is a sensitive, isothermal, transcription-
based amplification system designed specifically for 
the detection of RNA targets. RNA is extracted and 
bound to silica beads. Nucleic acid is amplified using 
specific primers. The amplified RNA is hybridized to 
capture probes attached to magnetic beads, and is 
detected by measuring electrochemiluminescence. 
The NucliSens EasyQ HIV-1 assay combines NASBA 
amplification with real-time detection using molecular 
beacons in a single step (Weusten et al., 2002).
• Hybrid capture signal amplification technology for 
quantifying viral DNA (e.g. Digene HC2 HBV DNA 
Test Plus, dynamic range: HBV, 1.42 x 105 to 1.7 x 109 
copies/ml). Target DNA combines with specific RNA 
probes to create RNA:DNA hybrids. Multiple RNA:
DNA hybrids are captured onto a solid phase coated 
with universal capture antibodies specific for RNA:
DNA hybrids and detected with alkaline phosphatase 
and chemiluminescent dioxetane substrate.
Careful consideration needs to be given when 
choosing a quantitative assay for determining viral load. 
Commercial kits are usually validated using a large cohort 
of clinical samples. Development of in-house assays may 
be achieved if a properly structured validation procedure is 
implemented. However, regulatory requirements in some 
countries may restrict the diagnostic use of such in-house 
assays, e.g. in Australia for tests required to comply with 
the Therapeutic Goods Administration (TGA), such as for 
HIV and HCV.
Issues affecting real-time PCR results
It is important to recognize a number of issues that may 
impact on the performance of real-time PCR assays.
Firstly, sequence information available on public 
databases such as GenBank may be limited or may not 
accurately reflect sequence data for micro-organisms 
circulating in the local population. This was demonstrated 
in a real-time PCR assay for herpes simplex virus (HSV) 
published by Espy et al. (2000), which, when applied in 
our laboratory, incorrectly typed some HSV type 1 as 
HSV type 2 by melting curve analysis. The reason was 
that local strains of HSV type 1 differed in sequence from 
those used to validate the assay described by Espy et 
al., and this sequence variation resulted in a change in 
melting temperature consistent to that for HSV type 2 
(Whiley and Sloots, 2005a).
Another important limitation of melting curve analysis 
is its inability to detect two viral types (or viral strains) using 
common primers, if both are present simultaneously in a 
single specimen. This was demonstrated in a real-time 
PCR to distinguish JC and BK viruses by melting curve 
analysis developed in our laboratory. Our results showed 
that the relative viral loads of JCV and BKV in a single 
sample need only differ by one log for the assay to fail in 
the detection of both viruses (Whiley and Sloots, 2005a). 
Similar observations were also made for specimens 
collected from patients dually infected with HSV1 and 
HSV2.
Finally, sequence variation may also have a significant 
impact upon the accuracy of viral qPCR assays. Recently, 
we examined the impact of sequence mismatches in the 
primer target sites on qPCR. The results showed that as 
few as two mismatches in the 3′ end of a single primer 
could introduce considerable error, underestimating viral 
load by up to 3 logs (Whiley and Sloots, 2005b). The 
overall impact this has on qPCR results is dependent on 
the conditions used in the assay and may hinge on the 
nucleotide composition of the primers, the PCR annealing 
temperature, the reaction mix composition and the specific 
nucleotides that are the subject of mismatch.
Multiplex PCR
Multiplex PCR refers to the use of different pairs of primers 
to simultaneously amplify multiple nucleic acid regions 
from a sample. The term multiplex originally referred to a 
cinema with several movies shown simultaneously. In this 
context, multiplex PCR is the simultaneous amplification 
of multiple selected target regions with visualisation of the 
amplified products by gel electrophoresis, real-time PCR 
or detection with the use of digoxigenin (DIG)-labelled 
dUTP and antibodies to DIG (Roche Diagnostics, Basel, 
Switzerland). The main advantage of using multiplex 
PCR is to minimize the number of separate reactions, for 
example to detect a range of pathogens in one specimen, 
sequence variations for pathogen strain identification and 
analysis of multiple mutations or polymorphisms in genetic 
studies. Other advantages include conservation of time, 
reagents and samples that are of limited volume. The 
first reported use of multiplex PCR was the simultaneous 
amplification of multiple loci in the human Duchenne 
muscular dystrophy gene (Chamberlain et al., 1988).
Optimisation
The design and development of multiplex PCR is similar 
to that used in conventional PCR with a pair of primers 
specific for a selected region of the target sequence. These 
include optimisation of reaction components viz. primer 
designs (~20 nucleotides long and GC content of 40–60% 
with matched Tm values of 50–60
oC) concentrations of 
Mg2+, dNTP, primers, annealing and extension conditions. 
The concentrations of Mg2+ and dNTP used are generally 
higher in a multiplex PCR. Although it may be assumed 
that it is useful to design primers with similar Tm value, this 
may not necessarily yield similar annealing temperatures 
in the multiplex PCR. Similarly, primers with different Tm 
values may not necessarily yield vastly different annealing 
temperatures, due to empirical determinations of Tm values 
with different salt concentrations and assay conditions. 
Each of these reaction parameters needs to be titrated 
initially with matched primer pairs, in separate reactions, 
in order to determine optimal amplification efficiencies 
and detection sensitivities. This is then compared with the 
sensitivity of the multiplex PCR.
Asymmetric conditions
Having determined optimal PCR components and cycling 
conditions for each of the targets, in separate reactions, 
equimolar concentrations of primers can be used in the 
multiplex PCR. The optimal primer concentrations in the 
multiplex PCR would then be determined by subsequent 
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titrations to compare sensitivities for each of the targets. 
The primer concentrations would need to be increased for 
the target that showed weak amplification signals in the 
multiplex PCR. The term asymmetric PCR is sometimes 
used loosely to refer to different optimal concentrations 
of forward and reverse primers for the matched pair. 
This may be a result of maintaining optimal total primer 
concentrations, as well as other components, in the 
multiplex PCR. Subsequent optimal conditions would 
then be determined for the other reaction components 
and cycling conditions, by comparing test sensitivities and 
specificities with the single primer pair PCR. It may be 
helpful to use the same thermal cycler for all optimisations 
with the single and multiplex PCR to minimize variations.
Touchdown PCR
Touchdown PCR is a useful approach for rapid 
determination of the optimal cycling conditions, particularly 
during the development of real-time multiplex PCR. 
Starting with an initial annealing temperature several 
degrees higher than the calculated Tm, the temperature is 
progressively decreased by steps of 0.5oC – 2oC for one 
or two cycles per temperature increment, completing the 
amplification cycles at the lowest temperature increment. 
Subtracting 15–18 cycles (approximately the number of 
cycles for product to be detected in optimal conditions) 
from the cycle where the product is first detected (Ct), will 
suggest the optimal annealing temperature range. This 
can be further evaluated with additional real-time PCR 
assays using fixed annealing temperatures.
Buffers
There are commercially available buffers and Taq 
DNA polymerase (e.g. HotStartTaq, Qiagen GmbH, 
Hilden, Germany, and iQ Multiplex Powermix, Bio-Rad 
Laboratories, Hercules, CA, USA) that are prepared 
specifically for multiplex PCR with hot start conditions to 
minimize non-specific annealing of primers to templates 
and formation of primer dimers. Some of these buffers 
include ammonium ions (e.g. tetramethylammonium 
chloride) to destabilize the weak hydrogen bonds formed 
with non-specific priming. The commercially available 
multiplex PCR buffers may work well with a range of 
primers; however optimisation of the reaction components 
and cycling conditions is essential.
Commercially available buffers and manufacturers’ 
recommendations for multiplex PCR show convincing 
amplifications for each of the targeted sequences. 
However, these conditions have been optimized with 
purified target nucleic sequences or plasmid clones. In 
our experience, optimal PCR conditions may be different 
with purified targets titrated in buffers as against those 
with various specimen types. It is helpful to determine 
optimal conditions using specimens (spiked with the 
specific agents) that are known to be negative (Kok et 
al., 2000).
Real-time multiplex PCR
The advantages of real-time PCR over conventional PCR 
also apply to real-time multiplex PCR. Fluorescent probes 
with different excitation wavelengths can be used to 
detect and estimate the relative amounts of the amplified 
products. FRET single-labelled hybridization probes 
have two advantages over Taqman-type probes. Firstly, 
the length of the hybridisation target for FRET probes 
is approximately twice that Taqman probes, thereby 
increasing detection specificity. Secondly, analysis of the 
melting-point of the FRET probe-target hybrid provides 
presumptive strain differentiation. The following examples 
illustrate the use of real-time multiplex PCR to detect and 
subtype cutaneous viruses (herpes simplex and varicella 
zoster viruses) and respiratory viruses (influenza A and B 
and respiratory syncytial viruses).
Herpes simplex and varicella zoster virus detection 
and subtyping
One of the characteristic features of herpes virus infection 
is the ability to cause latency and subsequent reactivation. 
Two of the more common clinical manifestations of 
herpes simplex virus infection are cold sores and genital 
lesions. There are two subtypes of HSV, viz. HSV 1 and 
HSV 2. Reactivation with HSV 1 virus is reported to 
occur at a lower frequency than HSV 2 virus, with the 
latter commonly infecting genital sites (Simmons, 2002; 
Whitley and Gnann, 1993; Whitley et al., 1998). Chicken 
pox or varicella is caused by varicella zoster virus (VZV), 
a member of the herpes viruses (Connelly et al., 1993; 
Wharton, 1996). Herpes zoster (shingles) is seen mainly 
in adult life and is caused by reactivation of VZV in the 
previously infected person (Hope-Simpson, 1965). 
Isolation of these viruses in cell cultures take more than 
four days to yield a result and detection by immunoassays 
is not as sensitive, compared to PCR.
A real-time multiplex PCR is used for the detection, 
amplification and simultaneous subtyping of HSV 1 and 2 
and VZV viruses with FRET hybridisation probes (Burrows 
et al., 2002). The HSV primers amplify a 140 bp region of 
the DNA polymerase gene with LC Red 640 fluorophor 
as the acceptor probe. The VZV primers amplify a 162 
bp region of gene 29 with LC Red 705 fluorophor as the 
acceptor probe. The primers, FRET probes, PCR master 
mix reagents and extracted DNA from each specimen are 
mixed in one reaction tube. The presence of either HSV 
or VZV is detected in this multiplex PCR. HSV, if present, 
may be subtyped by melting temperature determination, 
with the FRET probe (LC 640) and HSV 2 target DNA 
hybrid melting at 72.5oC, HSV 1 at 58.2oC (Fig. 2a). The 
presence of VZV in the sample is confirmed with a melting 
temperature of 69.2oC with the specific FRET probe 
(LC705) (Fig. 2b). The limit of detection for these viruses 
is ~20 copies per reaction.
Respiratory viruses
Respiratory syncytial and influenza A and B viruses are 
the predominant respiratory viruses in countries with 
temperate climates. Infection rates are highest during 
the winter or wet season. Influenza A has caused four 
major pandemics during the past centuries viz. H1N1 
in 1918 and 1977 and H3N2 in 1957 and 1968 (www.
who.int). Influenza A viruses are differentiated by their 
haemagglutinin (HA) and neuraminidase (NA) surface 
glycoproteins, of which there are 16 HA and 9 NA subtypes. 
The various combinations of the influenza A subtypes are 
predominantly found in aquatic birds, ducks and geese. 
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Fig.  2. Melting temperature graphs of specific FRET hybridisation probe and target HSV and VZV viruses in a multiplex real time PCR with HSV and VZV 
primers and FRET hybridisation probes. (a) Differentiation of HSV1 (58.2oC) and HSV2 (72.5oC). The HSV FRET hybridisation probe (LC640) is homologous 
to HSV2. (b) The VZV FRET probe is labelled with LC705 and has a melting temperature at 69.2oC.
Influenza B infects humans only. The current circulating 
human strains of influenza A are HIN1 and H3N2. The 
trivalent, inactivated vaccine consists of these two strains 
and Influenza B.
Respiratory syncytial virus (RSV) is a major cause 
of paediatric bronchiolitis (>90%) and pneumonia (>50%) 
and is the most common cause of neonatal hospitalisation 
(Anonymous, 1978; Glezen et al., 1986). This virus is 
also a major cause of respiratory infections in adults 
(Falsey et al., 1995; Kok and Higgins, 1997) as well as 
the immunosuppressed and is responsible for 10% of 
hospitalisations. There are two subtypes of RSV, A and 
B. Both subtypes can co-circulate within the community 
during the same season. The isolation of RSV in cell 
cultures takes more than four days. Immunofluorescence 
and enzyme immunoassay tests have been widely used 
for rapid detection of RSV in respiratory exudate cells. 
However, these tests and isolation are not as sensitive 
as PCR.
We have developed an in-house multiplex real-time 
PCR that can detect and subtype these viruses (influenza 
A H1N1 and H3N2, influenza B, RSV-A and RSV-B) 
(Stone et al., 2004). The primers and FRET probes for 
these viruses and extracted RNA from each patient are 
included in the same reaction tube. The influenza A primers 
amplify the matrix gene with the use of FRET probes and 
LC705 that are designed to be homologous to H1N1. 
The influenza B primers amplify the haemagglutinin gene 
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Fig.  3. Melting temperature graphs of specific hybridisation probe and target influenza A, influenza B and RSV viruses in a multiplex real time PCR with 
the respective FRET hybridisation probes. (a) The influenza A FRET hybridisation probe (LC705) is homologous to influenza A H1N1 (68.3oC) and H3N2 is 
differentiated by a melting temperature at 63.5oC. (b) The influenza B FRET hybridisation probe (LC705) and target melts at 59.2oC (Figure  2a). The RSV 
FRET probe (LC640) is homologous to RSV subtype A and melts at 63.8oC. RSV subtype B has a lower melting temperature at 53.8oC.
with the use of FRET probes and LC705. The melting 
temperatures of influenza A H1N1, H3N2 and Influenza B 
are 68.3oC, 63.5oC and 59.2oC respectively, which provide 
well separated differentiation values (Fig. 3a). The RSV 
primers amplify the phosphoprotein gene with the FRET 
probes and LC640 homologous to subtype A (melting 
temperature 63.8oC). If RSV subtype B is detected, its 
melting temperature will be at 53.8oC (Fig. 3b). The limit of 
detection for these viruses is ~400 copies per reaction.
The use of sequence analysis
Sequencing of amplicons has proven to be a very 
useful diagnostic tool. As previously stated, this has 
resulted from the combination of economical and rapid 
sequencing chemistries, computer-based phylogenetic 
analysis software and electronic interrogation of Internet-
accessible gene sequence databases. Sequence 
analysis within diagnostic virology focuses in two main 
areas, (1) the phylogenetic analysis of strains to study 
the epidemiology of infectious outbreaks, and (2) the 
detection and monitoring of drug resistance-associated 
mutations associated with antiviral therapy.
Sequence-based phylogenetic analysis
Genotypic variation is akin to a ‘4 nucleotide base’ 
digital signal. With 400 character states per 100 bases 
of sequence, sequence-based phylogenetic analysis 
facilitates substantial resolution between strains, far 
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in excess of any phenotypic marker/s, although in 
reality, functional constraint on mutation restricts the 
number of informative sites to approximately 30–50 per 
100 bases, often to the redundant codon base sites in 
the protein-encoding regions normally targeted. The 
sequence analysis of amplicons obtained from positive 
samples allows for the very informative comparison of 
strain differences, to identify outbreaks, both for local 
community outbreaks affecting an isolated cluster of 
patients, and also to trace the global spread of important 
pandemic strains. To continue the example of the 
detection of noroviruses presented previously, while the 
conserved A and B regions within ORF-1 are very suitable 
for sensitive detection of genetically variable viruses, the 
more variable antigenic capsid-encoding regions within 
ORF-2 are far more phylogenetically informative (Kojima 
et al., 2002; Noel et al., 1997; Vinje et al., 2004). Such 
sequences also better reflect the immuno-selection to 
which the virus particles are subject during transmission 
in the community. Consequently, two regions within 
ORF-2 have been successfully targeted for subtyping of 
strains (designated regions C and D), resulting in 8 and 
17 subtypes of norovirus genotypes 1 and 2 respectively 
being recently proposed (Zheng et al., 2006). Such 
resolution is not possible when analysing sequence from 
regions A and B of ORF-1, and demonstrates the need 
to carefully consider which segment of a viral genome is 
to be targeted. The increased genetic variability of such 
sites can make successful amplification of product from 
these regions in all strains problematic, and highlights the 
often opposing issues of amplification sensitivity/broad 
reactivity and phylogenetic resolution which need to be 
balanced in designing a diagnostic amplification test. 
The use of sequence analysis software, such as Kodon 
(Applied Maths, Sint-Martens-Latem, Belgium), to correct, 
manage and compare sequences from an outbreak and 
with reference strains, is recommended.
Antiviral therapy and drug resistance-associated 
mutations
Highly potent antiviral therapies are available for treating 
a number of viral infections, such as HIV, HBV, HCV, 
influenza virus and herpes viruses including CMV, HSV 
and VZV. Antiviral therapies interfere with viral replication 
that is intimately associated with the host cell and 
therefore are also toxic to the host. They target viral-
encoded enzymes required for viral replication, such as 
protease inhibitors (PI), nucleoside and non-nucleoside 
reverse-transcriptase inhibitors (NRTI and NNRTI) and 
more recently fusion inhibitors (FI) for HIV, reverse-
transcriptase inhibitors for HBV and protein kinase (UL97) 
and DNA polymerase (UL54) inhibitors for CMV.
Drug resistance and resistant mutants
The virus’s ability to develop resistance to antiviral drugs 
has become the focus of physicians since 1996 with the 
arrival of Highly Active Antiretroviral Therapy (HAART) 
for treating HIV (Mirken, 1997; Stephenson, 1997). Since 
then, drug-resistant strains in other viral infections such 
as chronic HBV and immuno-compromized patients 
infected with herpes viruses have also been reported with 
increasing frequency (Chou et al., 2003; Ono-Nita et al., 
1999; Springer et al., 2005; Tipples et al., 1996; Xiong et 
al., 2000). The development of drug resistance is caused 
by multiple factors; (a) the kinetics or dynamics of viral 
production and viral clearance, (b) error proneness of the 
viral reverse transcription, (c) structural flexibility of viral 
enzymes, (d) the potency of antiviral drug combinations, 
(e) the pharmaco-kinetic properties of the antiviral drug, 
(f) the mutations selected by target-specific drugs, (g) 
the patient’s prior drug experience, and (h) the patient’s 
adherence to therapy (Richman, 2000).
Viral fitness of resistant mutants
It has been reported that drug-resistant mutants have 
reduced fitness (replication capacity) compared with 
drug-susceptible variants in vitro (Lucas, 2005; Melegari 
et al., 1998). Persistence of drug-resistant variants with 
reduced replication capacity may offer some clinical 
benefit (Buckheit, 2004; Hirsch et al., 2003; Springer et 
al., 2005). However, the benefits may be reduced by 
compensatory mutations in other regions that restore 
impairment of fitness. As a result, the risk of resistant 
mutants being transmitted to susceptible individuals is 
increased. Therefore, combination therapy to completely 
suppress ongoing replication is recommended to prevent 
the emergence of resistance mutations (Richman, 2000).
Transmission of resistant mutants
In 1998, Hecht and colleagues reported the first 
documented case of high-level resistance to protease 
inhibitors in a newly infected treatment-naive HIV patient 
(Hecht et al., 1998). Since this initial report, there have 
been many reports on the transmission of resistance 
mutations (Erice et al., 1993). It is believed that while 
HAART is improving both the length and quality of life 
in HIV patients, resistant strains arise when the patient 
compliance is poor. When these resistant strains are 
transmitted to susceptible individuals, choosing an 
effective treatment regimen for them can be difficult. If 
the resistance profile is unknown, sub-optimal first-line 
therapy will result (Tang and Pillay, 2004).
Determination of drug resistance profiles
The right treatment regimen will lead to a greater 
chance of long-term success and a reduced possibility 
of developing drug resistance. A suitable test is required 
to determine drug resistance profiles, both in treatment-
naive patients and for viral rebound in patients already on 
treatment, to establish if resistance has developed which 
requires a change in treatment (Mirken, 1997). Two types 
of resistance testing assays have since been developed; 
phenotypic and genotypic assays. Phenotypic assays test 
the actual ability of the infecting virus, or its relevant gene 
inserted into a recombinant virus, to replicate in cell culture 
in the presence of a drug or drugs. Genotypic tests, on the 
other hand, identify specific genetic mutations in the virus 
which correlate with phenotypic resistance (Hirsch et al., 
2003; MacArthur, 2004). Multiple studies have shown 
that either genotypic antiretroviral resistance testing 
or phenotypic antiretroviral resistance testing provides 
useful information to help achieve a better short-term 
virological outcome in patients who are about to start their 
next antiretroviral regimen (Baxter et al., 2000; Cohen et 
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al., 2002; Durant et al., 1999; Tural et al., 2002). While 
phenotyping and genotyping show excellent correlation 
(R2 > 0.8) for HIV (Hirsch et al., 2003), neither phenotyping 
nor genotyping can effectively detect all resistant strains in 
the case of herpes virus infection in immunocompromized 
patients. A combination of phenotypic and genotypic 
assays is recommended for the complete analysis of 
antiviral resistance in herpes virus infections (Andrei et 
al., 2001; Chou et al., 2003; Gilbert and Boivin, 2003; 
Scott et al., 2004). Phenotyping is cumbersome to 
perform, time-consuming and expensive, and therefore 
not readily available in general laboratories. Such issues 
restrict the practical worth of phenotyping to confirm the 
clinical outcome. Genotypic assays, on the other hand, 
are faster and less expensive, and as a consequence 
are now in much wider use (MacArthur, 2004). Currently, 
there are three types of genotyping assays available, 
Dideoxynucleotide Terminator Cycle Sequencing 
(DTCS), DNA Chips (High-density oligo-nucleotide 
arrays, e.g. Affimetrix) and Point Mutation Assays (e.g. 
InnoLipa). DTCS may be performed using assay kits (e.g. 
TRUGENE™ HIV-1 Genotyping Kit, [Visible Genetics, 
Suwanee, GA], or ViroSeq™ HIV-1 Genotyping System 
[ABI]) or in-house techniques (Gunthard et al., 1998) 
and is the most common genotyping method in use. It 
involves a PCR amplification (or RT-PCR for RNA viruses) 
of the target region in the viral gene, followed by cycle 
sequencing of the amplified gene using dye terminator 
chemistry and analysed by a DNA analyser (e.g. ABI 3700 
DNA Analyser). The specific viral sequence is then edited 
using an editing program (e.g. Windows-based Kodon 
[Applied Maths] or Macintosh-based Sequence Navigator 
[ABI]). The interpretation of resistance profiles can be 
very complicated since, as mentioned earlier, patients are 
most likely to receive combination treatment. Although it 
is important to learn the resistance profile of individual 
drugs, consideration should also be given to drug-drug 
interactions. It is particularly important to choose a 
suitable combination treatment with non-overlapping 
toxicity profiles and complementary resistance profiles 
(Richman, 2000).
For HIV genotyping using in-house assays, 
interpretation of resistance profiles can easily be 
achieved by submitting the sequence from the patient to 
one of the readily available data bases e.g. Stanford HIV 
Drug Resistance Database (http://hivdb.stanford.edu) or 
Los Alamos National Laboratory – HIV Drug Resistance 
Database (resdb.lanl.gov/Resist_DB/default.htm) or 
commercially available interpretation programs. However, 
Sturmer and colleagues reported some inconsistencies 
in the interpretation between nine different resistance 
interpretation systems (Sturmer et al., 2003). Therefore, 
before selecting an interpretation system, it is essential 
to find out how the system is managed and, in particular, 
how often the system is updated and whether references 
for individual mutations are available (Johnson et al., 
2005).
Unlike HIV, patients infected with HBV often only 
receive monotherapy. Resistance mutations usually 
develop within a few months of lamivudine monotherapy. 
Because of the overlapping reading frame of the hepatitis 
B surface antigen, drug resistance mutations in the DNA 
polymerase also impact on hepatitis B surface antigen 
and its function. Therefore, both Pol and S reading frames 
must be analysed when interpreting resistance profiles 
(Bozdayi et al., 2004; Oon et al., 1999; Richman, 2000). 
Confusion can arise from inconsistent numbering of amino 
acids within the HBV polymerase, the result of amino acid 
insertions or deletions which occur frequently among the 
variable HBV genotypes. A more consistent consensus RT 
domain numbering system has recently been proposed 
which is independent of genotype variability, allowing a 
standardized analysis of amino acid changes (Stuyver et 
al., 2001).
Recent developments and the future
Several new antiretroviral agents are currently being 
developed, with some already in clinical trials. The 
functions of these agents are listed below:
• Inhibiting HIV Integrase protein
• Targeting the ejection of zinc ions from zinc finger 
proteins
• Inhibiting all steps of viral entry
• Interacting with Tat/Tar viral proteins
• Targeting other unexploited cellular (Tsg101, 
APOBEC3G) or viral (Vif, Rev or Rnase H) proteins 
(Barbaro et al., 2005).
In recent years, the application of gene therapy in 
viral infections has become a major research focus in an 
attempt to search for alternatives to the current anti-viral 
therapy. The use of ribozyme and small antisense RNA to 
inhibit HIV replication has shown some promise in vitro. 
Such therapies may replace the current treatments and 
the need to monitor drug resistance profiles. (Puerta-
Fernandez et al., 2005; Shankar et al., 2005; Wolkowicz 
and Nolan, 2005).
Conclusions
As molecular methods have evolved and facilitated a 
major contribution to the diagnosis of human viral disease, 
there has been an increasing awareness for the need for 
quality assurance in order to produce clinically relevant 
results. In addition, the targeted nature of PCR brings 
with it some inherent limitations that are difficult to control, 
particularly in virology, where the heterogeneous nature of 
the viral genome may lead to difficulties in assay design 
and performance. Nevertheless, an awareness of these 
issues will ultimately result in a better understanding of 
this new technology, and enable the full exploration of the 
potential of these modern diagnostic tools.
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